WO2014176900A1 - 皂苷纳米胶束及其制备方法、应用和药物组合物 - Google Patents
皂苷纳米胶束及其制备方法、应用和药物组合物 Download PDFInfo
- Publication number
- WO2014176900A1 WO2014176900A1 PCT/CN2013/088558 CN2013088558W WO2014176900A1 WO 2014176900 A1 WO2014176900 A1 WO 2014176900A1 CN 2013088558 W CN2013088558 W CN 2013088558W WO 2014176900 A1 WO2014176900 A1 WO 2014176900A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ginsenoside
- saponin
- glc
- type
- content
- Prior art date
Links
- 0 CC(CCC=C(C)C)([C@@](CC1)C([C@](*)C2)[C@]1(C)[C@](C)(C[C@@]1*)C2[C@]2(C)C1C(C)(C)[C@](*)CC2)O Chemical compound CC(CCC=C(C)C)([C@@](CC1)C([C@](*)C2)[C@]1(C)[C@](C)(C[C@@]1*)C2[C@]2(C)C1C(C)(C)[C@](*)CC2)O 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J17/005—Glycosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
Definitions
- the invention belongs to the field of medicaments, and in particular relates to a saponin nanomicelle and a preparation method, application and pharmaceutical composition thereof. Background technique
- the polymer micelles are generally characterized by being amphiphilic, that is, having both a hydrophilic group and a hydrophobic group.
- the hydrophobic group generally forms an inner core in the middle, and the hydrophilic group is generally arranged to form an outer shell, and the polymer formed by the polymerization can be fat-soluble.
- the pharmaceutical ingredient is encapsulated in the hydrophobic center of its polymeric micelles to form a drug-loaded polymeric micelle and can be dissolved in water or alcohol with its hydrophilic end.
- Polymer micelles can encapsulate fat-soluble drug molecules inside the micelles, prolong the cycle time and biological half-life of the drug in the blood, increase the accumulation of drugs in the lesions, reduce adverse reactions, and can be connected to special carriers, antibodies or The body is capable of binding to a receptor of a target cell to enhance the therapeutic effect.
- most of the researches on the use of micelles as drug carriers were prepared by using polymer micelles. Representative of such polymer micelles were poly-L-glutamic acid, poly-L-lysine, and more. Sugar polymers such as chitin and chitosan.
- Tween 80 which is the most commonly used in the Tween series
- Tween 80 certain additives such as Tween 80, which is the most commonly used in the Tween series, are added, but these additives often have certain side effects.
- the lipophilic ingredients in Tween 80 include unsaturated fatty acids, which are easily oxidatively degraded to produce more toxic components, and the resulting side effects will outweigh the benefits of the product itself.
- the medical profession confirmed that Tween 80 is used in injections and can cause allergic reactions, including shock, dyspnea, hypotension, angioedema, rubella and other allergic reactions. These adverse reactions can be very serious in human clinical trials, and even deaths are reported. Therefore, relevant standards for pharmaceuticals, foods and health care products have strict regulations on the safe use limits of Tween 80.
- Other types of polymer micelles in the prior art also have problems in terms of preparation and physiological availability.
- Saponin compounds include natural saponin compounds as well as artificial semi-synthesized saponin compounds.
- natural saponin compounds such as ginsenosides and notoginsenosides have been modified by relatively mature techniques, and various semi-synthetic saponin derivatives have been obtained.
- the invention patent application of the patent application No. CN200910217947.7, the application publication No. CN101824065A, the ginsenoside secondary glycoside Rhl is modified; the patent application No. CN201110054137.1, the application patent of the publication No. CN102174191A is also disclosed.
- a method for preparing a saponin compound such as ginsenoside by using polyethylene glycol a method for preparing a fatty acid ester compound of ginsenoside Rh2 by a patent application No. CN201010548971.1, application No. CN102603847A; Patent Application No. CN201210207368 .6, the invention patent application of the publication No. CN102766187A, discloses four ester derivatives of ginsenoside Compoimd-K and preparation method thereof; "Experimental study on ginsenoside Rgl PEG modification and stability" (Liu Mei, Wang Li, Hu Kaili, Feng Jiggling, Chinese Journal of Traditional Chinese Medicine, Vol. 37, No.
- Reverse micelle refers to an agglomerate (self-organized system) in which a certain amount of amphiphilic substances spontaneously form in a non-polar organic solvent, wherein the polar group of the amphiphilic substance faces the inside of the micelle, and the non-polar group faces the glue.
- the outer continuous phase of the oil, the polar environment inside the reverse micelles allows it to solubilize the water soluble material.
- the reverse micelle can increase the stability of the drug, and can be converted into a liquid crystal junction after contact with body fluid. Structure, retarding the dissolution of the drug, thereby achieving a slow release release administration. It can also be used as a carrier for transdermal drug delivery systems.
- reverse micelles can also be used as a nanoparticle preparation technique.
- the nanoparticles prepared by the method have the characteristics of small particle size and narrow distribution.
- the commonly used reverse micelles are lecithin reverse micelles and Sodium Di-2-Ethylhexyl Sulfosuccinate (AOT) reverse micelles.
- the technical problem to be solved by the present invention is to solve the problem that the fat-soluble drug is hardly soluble in water or the water-soluble drug is insoluble in the lipid solvent, and the existing polymer micelle or reverse micelle drug-loading ability is not ideal, and the biological A defect of poor compatibility, providing a saponin nanomicelle and a preparation method, application and pharmaceutical composition thereof.
- ginsenosides and/or notoginsenosides having certain structures can be taken from the roots, stems, leaves, fruits, etc. of the Araliaceae plant, or Synthetic, one or more of the saponins can be used to prepare saponin nanomicelles, which can be used as a cosolvent or compound preparation for antitumor drug ingredients, cosmetically insoluble ingredients and health food poorly soluble ingredients, among which
- the bundle can be used as a drug-loaded micelle which is insoluble in water-soluble fat-soluble pharmaceutical ingredients, and the ginsenoside and/or notoginsenoside component used is naturally non-toxic, has no toxic side effects, and has an excellent effect.
- the reverse micelle prepared by saponin can be used as a cosolvent or a combination preparation of a water-soluble drug or a water-soluble component, and can also be used as a drug-loaded micelle of a water-soluble drug or a component.
- the present invention solves the above technical problems by the following technical solutions.
- the present invention provides a saponin nanomicelle comprising one or more saponins as shown in Formula 1;
- R 2 are each independently -H or a hydrophilic group
- R 3 is -H or -OH
- R 4 is a lipophilic group.
- the hydrophilic group is a hydrophilic group in the conventional sense of the art.
- the hydrophilic group is preferably -OH, a glycosyl group, a modified sugar group, a fatty acyl group, an amino acid group, an organic acid ester group, and a sulfate.
- the modified sugar group is preferably a polymer type modified sugar group, a fatty acyl modified sugar group, an amino acid group modified sugar group or an organic acid ester group modified sugar group.
- 1 ⁇ and 12 are preferably not -H at the same time.
- R 6 is any one of the following groups: -0-Glc, -0-Rha, -0-Lyx, -O-XyK-O-Ara(p), -O -Ara(f), -0-Glc(2 ⁇ l)Glc (number indicates carbon position, the same below), -0-Glc(6 ⁇ l)Glc, -0-Glc(2 ⁇ l)Rha, -0 -Glc(2 ⁇ l)XyK -0-Glc(6 ⁇ l)Xyl, -0-Glc(6 ⁇ l)Rha, -0-Glc(2 ⁇ l)Ara(p), -0-Glc(6 ⁇ l) Ara(p), -0-Glc(2 ⁇ l)Ara(f), -0-Glc(6 ⁇ l)Ara(f), -0-Glc(2 ⁇ l)Glc(2 ⁇ l ) G
- R 7 , R 7 is a group formed by substituting one or more of the hydroxyl groups in the above, wherein R 5 is any one of the following groups:
- a linear fatty acyl group a phosphate group, a succinate group, a n-butyrate group, a sulfonate group, a malate group or a sodium sulfate salt of ID c 4 to c 22 ;
- Boc-glycine Gly
- Boc-alanine Ala
- Boc-arginine Arg
- Boc-lysine Lys
- Boc-serine Ser
- acetophenine Ac) -Phe-OH
- Acetylproline Ac-Pro-OH
- Acetylphenylalanine Ac-Phe-OH
- Asparagine Asn
- Aspartic Acid Asp
- Cysteine (Cys) glutamine
- glutamic acid Glu
- Histidine Histidine
- isoleucine Ile
- leu Leu
- methionine Metal
- phenylalanine Phe
- R 8 and R 8 are any of the following groups:
- a linear fatty acyl group a phosphate group, a succinate group, a n-butyrate group, a sulfonate group, a malate group or a sodium sulfate salt of ID c 4 to c 22 ;
- Boc-glycine Gly
- Boc-alanine Ala
- Boc-arginine Arg
- Boc-lysine Lys
- Boc-serine Ser
- acetophenine Ac) -Phe-OH
- Acetylproline Ac-Pro-OH
- Acetylphenylalanine Ac-Phe-OH
- Asparagine Asn
- Aspartic Acid Asp
- Cysteine (Cys) glutamine
- glutamic acid Glu
- Histidine Histidine
- isoleucine Ile
- leu Leu
- methionine Metal
- phenylalanine Phe
- the molecular weights of the PEG, PEO, PVP and EPEG are preferably independently from 200 to 20000.
- the linear fatty acyl group may be an acyl group of a naturally occurring saturated or unsaturated linear fatty acid, and an acyl group of a synthetic saturated or unsaturated linear fatty acid, preferably a stearyl group or a palmitoyl group.
- Glc in -O-Glc is: ; at -O-Ara(p)
- ⁇ is preferably R 6 a group formed by substituting 1 to 4 hydroxyl groups in the above;
- R 6 is -0-Glc(2 ⁇ l)Glc, -0-Glc(6 ⁇ l)Glc, -0-Glc(2 ⁇ l)Rha, -0-Glc(2 ⁇ l)Xyl, -0 -Glc(6 ⁇ l)Xyl, -0-Glc(6 ⁇ l)Rha, -0-Glc(2 ⁇ l)Ara(p), -0-Glc(6 ⁇ l)Ara(p), -0 -Glc(2 ⁇ l)Ara(f) , -0-Glc(6 ⁇ l)Ara(f) , -0-Glc(2 ⁇ l)Lyx or -0-Glc(6 ⁇ l)Lyx, R 7 is preferred for R 6 1 ⁇ 7 hydroxyl groups of the R 5 groups is substituted with the formed;
- R 6 is -0-Glc(2 ⁇ l)Glc(4 ⁇ l)Xyl, -0-Glc(2 ⁇ l)Glc(2 ⁇ l)Rha, -0-Glc(2 ⁇ l)Glc(2 ⁇ l) Lyx, -0-Glc(2 ⁇ l)Glc(2 ⁇ l)Ara(f), -0-Glc(2 ⁇ l)Glc(2 ⁇ l)Ara(p), -0-Glc( 2 ⁇ l) Glc(6 ⁇ l)Glc, -0-Glc(2 ⁇ l)Glc(6 ⁇ l)Rha, -0-Glc(2 ⁇ l)Glc(6 ⁇ l)Xyl, -0-Glc (2 ⁇ l) Glc(6 ⁇ l)Lyx, -0-Glc(2 ⁇ l)Glc(6 ⁇ l)Ara(f), -0-Glc(2 ⁇ l)Glc
- the lipophilic group is an oleophilic group in the conventional sense of the art.
- it is preferably a group represented by Formula 2, Formula 3 or Formula 4; Formula 2; wherein R 9 , R 1Q and R are the thiol groups of ( ⁇ 3 , d is Equation 3; where, R 12 , ! ⁇ ⁇ ⁇ base, e is an integer from 1 to 3; Wherein R 15 and R 16 are each independently ( ⁇ ( 3 ⁇ , f is an integer of 1 to 3), in the present invention, R 4 is 2-1, 3-1 or 4- a group as shown in 1;
- the saponin represented by Formula 1 is a type A saponin, a type B saponin, and a type C saponin; or, preferably, the saponin nanomicelle,
- the saponin of the formula 1 is a type B saponin and/or a type C saponin; wherein the type A saponin is one or more of the saponins of the formula 1-1, and the type B saponin is of the formula One or more of saponins represented by 1-2, wherein the C-type saponin is one or more of saponins as shown in Formula 1-3;
- the saponin represented by Formula 1 when the saponin represented by Formula 1 is the A saponin, the B saponin and the C saponin, the molars of the saponin A, the saponin B and the saponin C More preferably (0.8 ⁇ 1.2) : (1.8-2.2) : (0.8 ⁇ 1.2).
- the saponin represented by Formula 1 is the B-type saponin and/or the C-type saponin, and the saponin nanomicelle does not contain the Type A saponin.
- the saponin nanomicelles of the present invention can be classified into saponin nanopositive micelles and saponin nano reverse micelles.
- the saponin nano-positive micelles have the characteristics of encapsulating a fat-soluble drug component
- the saponin nano-anti-micelle It has the characteristics of wrapping water-soluble pharmaceutical ingredients.
- the saponin nanomicelle is a saponin nanopositive micelle, such as Rg5 type ginsenoside nanopositive micelle, Rg5/Rkl type ginsenoside nanopositive micelle, Rg3/Rg5/Rkl type ginseng saponin nanopositive micelle;
- the saponin nanomicelle is a saponin nano reverse micelle;
- the saponin nanomicelle is a saponin nano Positive micelles, such as HSE-type ginsenoside nano-nose micelles, Rg2/Rk4/Rg6-type ginsenoside nano-nano micelles.
- the saponin nanomicelle may be formed from one or more saponins as shown in Formula 1.
- mass content means the mass percentage content of the substance to the total mass of the saponin nanomicelle
- molar content means the molar percentage content of the substance in the molar amount of the total substance in the saponin nanomicelle.
- the saponin nanomicelle is formed of one type of saponin as shown in Formula 1, the saponin is the saponin, B-type saponin or C-type saponin; the mass content of the saponin It is 70% or more, preferably 80% or more, more preferably 90% or more, and most preferably 95% or more.
- saponin nanomicelles formed by ginsenoside Rg5, ginsenoside Rk1, ginsenoside Rk4, and ginsenoside Rg6, respectively, wherein ginsenoside Rg5 and ginsenoside Rkl form ginsenoside nanopositive micelles
- ginsenoside Rk4 and the ginsenoside Rg6 form a ginsenoside nano reverse micelle.
- the saponin nanomicelle is formed of the type B saponin or the type C saponin, and the saponin has a molar content of 70% or more, preferably 80% or more, more preferably 90%. Above, it is optimally above 95%.
- the saponin nanomicelle is formed by two types of saponins as shown in Formula 1, that is, the saponin is any two saponins of the saponin, the saponin and the saponin;
- the mass content of the two saponins is respectively above 25%, and the total mass content of the two saponins is above 70%; preferably, the mass ratio of the two saponins is 0.8 to 1.2, and the total mass of the two saponins
- the content is above 90%; more preferably, the mass ratio of the two saponins is 1:1, and the total mass content of the two saponins is above 95%.
- ginsenoside Rg5 and ginsenoside Rkl form Rg5/Rkl type ginsenoside nanopositive micelles
- ginsenoside Rk4 and ginsenoside Rg6 form Rk4/Rg6 type ginsenoside nano reverse micelles.
- the saponin nanomicelle is formed of the type B saponin and the type C saponin, and the molar content of the type B saponin and the type C saponin is respectively 25% or more, and the type B saponin and the type C are respectively
- the total molar content of the saponin is 70% or more; preferably, the molar ratio of the type B saponin to the type C saponin is 0.8 to 1.2, and the total molar content of the type B saponin and the type C saponin is 90%. More preferably, the molar ratio of the B-type saponin to the C-type saponin is 1:1, and the total molar content of the B-type saponin and the C-type saponin is 95% or more.
- the saponin nanomicelle is formed of three types of saponins as shown in Formula 1, that is, the saponins are the saponins A, B saponins and C saponins, the saponins A
- the mass content of the type B saponin and the type C saponin is respectively 15% to 45%, and the total mass content of the type A saponin, the type B saponin and the type C saponin is 70% or more;
- the mass content of the type A saponin is 15% to 25%
- the mass content of the type B saponin is 35% to 45%
- the mass content of the type C saponin is 15% to 25%
- the total mass content of the type A saponin, the type B saponin and the type C saponin is 80% or more; more preferably, the mass ratio of the type A saponin, the type B saponin and the type C saponin Is (0.8 to 1.2): (1.8-2.2): (0.8 to 1.2), and the total mass content of the type A saponin, the type B saponin, and the type C saponin is 90% or more; optimally, The mass ratio of the type A saponin, the type B saponin and the type C saponin is 1:2: 1, and the total mass content of the type A saponin, the type B saponin and the type C saponin is above 95.
- ginsenoside Rg3, ginsenoside Rg5 and ginsenoside Rkl form Rg3/Rg5/Rkl type ginsenoside nanopositive micelles
- ginsenoside Rh2 ginsenoside Rh3 and ginsenoside Rk2 form Rh2/Rh3/ Rk2 type ginsenoside nanopositive micelles
- ginsenoside Rg2, ginsenoside Rk4 and ginsenoside Rg6 form Rg2/Rk4/Rg6 type ginsenoside nano reverse micelles.
- type A saponin ginsenoside Rg2, ginsenoside Rg3, ginsenoside Rhl
- type B saponin ginsenoside Rg5, ginsenoside Rk4, ginsenoside Rh4, and type C saponin: ginsenoside Rkl, ginseng Saponin Rg6 and ginsenoside Rk3 together form HSE-type ginsenoside nanopositive micelles.
- the saponin nanomicelle is formed of the type A saponin, the type B saponin and the type C saponin, and the molar content of the type A saponin, the type B saponin and the type C saponin 15% ⁇ 45%, respectively, the total molar content of the type A saponin, the type B saponin and the type C saponin is above 70%;
- the molar content of the type A saponin is 15% to 25%
- the molar content of the type B saponin is 35% to 45%
- the molar content of the type C saponin is 15% to 25%
- the total molar content of the type A saponin, the type B saponin and the type C saponin is 80% or more; more preferably, the molar ratio of the type A saponin, the type B saponin and the type C saponin Is (0.8 to 1.2): (1.8-2.2): (0.8 to 1.2), and the total molar content of the type A saponin, the type B saponin, and the type C saponin is 90% or more; optimally, The molar ratio of the type A saponin, the type B saponin and the type C saponin is 1:2:1, and the total molar content of the type A saponin, the type B saponin and the type C saponin is above 95.
- the saponin nano-nano micelle has the amphiphilic property of the ordinary polymer micelle, that is, has both a hydrophilic group and a hydrophobic group.
- the hydrophobic group forms an inner core in the middle, and/or is a hydrophilic group, and is arranged outside the micelle to form an outer shell.
- the saponin nanomicelle can encapsulate the fat-soluble drug component in the hydrophobic center of the micelle to form a drug-loaded micelle. And can be dissolved in water or alcohol with its hydrophilic end.
- the saponin nano-positive micelles can encapsulate the fat-soluble drug molecules into the micelle, prolong the circulation time and biological half-life of the drug in the blood, increase the accumulation of the drug in the lesion, and reduce the adverse reactions.
- a special vector, antibody or ligand can be attached to enable binding to the receptor of the target cell to enhance the therapeutic effect.
- the saponin nano reverse micelle has the amphiphilic property of a conventional polymer reverse micelle, that is, has both a hydrophilic group and a hydrophobic group.
- the hydrophilic group forms an inner core in the middle, and/or is a hydrophilic group, and is arranged in the micelle to form a hydrophilic center.
- the saponin nanomicelle can encapsulate the water-soluble drug component in the hydrophilic center of the micelle to form a carrier. It has a reverse micelle of the drug and can be dissolved in the ester or oil with its hydrophobic end.
- the saponin nano reverse micelle can encapsulate the water-soluble drug molecule into the inside of the micelle, prolong the circulation time and biological half-life of the drug in the blood, increase the accumulation of the drug in the lesion, reduce the adverse reaction, and can be connected with a special carrier and antibody. Or a ligand that binds to a receptor of a target cell to enhance the therapeutic effect.
- the saponin represented by Formula 1 is mainly derived from a ginsenoside raw material and/or a notoginsenoside raw material, such as ginsenosides and notoginsenosides processed from the plant of the genus Araliaceae or the genus Gynostemma. analog.
- the saponin nanomicelle in addition to the saponin as shown in Formula 1, the remaining components may be regarded as non-essential components, which are generally unavoidable impurities, usually in addition to A-type saponin, B-type saponin and C-type.
- Other types of ginsenosides and/or notoginsenosides other than saponins that is, compounds represented by Formula 1.
- Ginsenoside Rg5 Ginsenoside Rkl: Ginsenoside Rg3: 7; Ginsenoside Rh2: Ginsenoside Rh3: Formula 9; Ginsenoside Rk2: Formula 10: Ginsenoside Rg2:
- Ginsenoside Rhl 2013/088558 Ginsenoside Rk4: ;
- the saponin nanomicelle which is a Rg5 type ginsenoside nanopositive micelle, comprises ginsenoside Rg5, and the ginsenoside Rg5 has a mass content of 50% or more.
- the content of the ginsenoside Rg5 is preferably 70% or more, further preferably 85% or more, more preferably 90% or more, and most preferably 95% or more.
- the saponin nanomicelle comprising ginsenoside Rg5, wherein the ginsenoside Rg5 has a molar content of 50% or more, preferably 70% or more, further preferably 85% or more, more preferably Above 90%, optimally above 95%.
- the ginsenoside Rg5 is derived from the ginsenoside Rg5 monomer obtained by the above-mentioned ginsenoside raw material after acid hydrolysis and purified.
- all of the components other than the ginsenoside Rg5 are other kinds of ginsenosides.
- ginsenoside Rg5 ginsenoside Rg5
- ginsenoside Rk1 ginsenoside Rs5
- ginsenoside Rk2 ginsenoside Rh3, ginsenoside Rs4
- any of said type B saponins and said type C saponin are hydrophilic groups and are -11
- ginsenosides of -OH can also form saponin nanopositive micelles.
- the saponin nanomicelle which is a Rkl type ginsenoside nanopositive micelle, comprises ginsenoside Rkl, the ginseng soap The ground is at least 85%, more preferably at least 90%, and most preferably at least 95%.
- the saponin nanomicelle comprising ginsenoside Rkl, the ginsenoside
- the molar content of Rkl is 50% or more, preferably 70% or more, further preferably 85% or more, more preferably 90% or more, and most preferably 95% or more.
- the ginsenoside Rkl is derived from the ginsenoside Rkl monomer obtained by acidolysis of the above-mentioned ginsenoside raw material and purified.
- all of the components other than the ginsenoside Rk1 are other kinds of saponins.
- the saponin nanomicelle which is a Rk4 type ginsenoside nano reverse micelle, comprises ginsenoside Rk4, and the ginsenoside Rk4 has a mass content of 50% or more.
- the content of the ginsenoside Rk4 is preferably 70% or more, further preferably 85% or more, more preferably 90% or more, and most preferably 95% or more.
- the saponin nanomicelle comprising ginsenoside Rk4, wherein the ginsenoside Rk4 has a molar content of 50% or more, preferably 70% or more, further preferably 85% or more, more preferably Above 90%, optimally above 95%.
- the ginsenoside Rk4 is derived from the ginsenoside Rk4 monomer obtained by acid hydrolysis of the ginsenoside raw material and purified.
- the remaining components are other kinds of saponins.
- ginsenoside Rk4 ginsenoside Rk3, ginsenoside F4, ginsenoside Rs7, ginsenoside Rh4, ginsenoside Rs6, ginsenoside Rg6, notoginsenoside T5 or any of said type B saponins and said type C saponin Ginsenosides, wherein -OH, and R 2 is a hydrophilic group, can also form saponin nano reverse micelles.
- the saponin nanomicelle which is a Rg6 type ginsenoside nano reverse micelle, comprising ginsenoside Rg6, the ginseng soap
- the mass content of the glycoside Rg6 is 50% or more.
- the ginsenoside Rg6 preferably has a mass content of 70% or more, further preferably 85% or more, more preferably 90% or more, most preferably 95% or more.
- the saponin nanomicelle comprises ginsenoside Rg6, and the ginsenoside Rg6 has a molar content of 50% or more, preferably 70% or more, further preferably 85% or more, more preferably Above 90%, optimally above 95%.
- the ginsenoside Rg6 is derived from the ginsenoside Rg6 monomer obtained by the above-mentioned ginsenoside raw material after acid hydrolysis and purified.
- the remaining components are all other types of saponins except for the ginsenoside Rg6.
- the saponin nanomicelle which is a Rg5/Rkl type ginsenoside nanopositive micelle, comprising ginsenoside Rg5 and ginsenoside Rkl, the mass content of the ginsenoside Rg5 Above 15%, the ginsenoside Rk1 has a mass content of 15% or more, and the total mass content of the ginsenoside Rg5 and the ginsenoside Rk1 is 50% or more.
- the ginsenoside Rg5 has a mass content of 25% or more
- the ginsenoside Rk1 has a mass content of 25% or more
- the total mass content of the ginsenoside Rg5 and the ginsenoside Rkl is 80%. %the above;
- the ginsenoside Rg5 has a mass content of 25% to 60%
- the ginsenoside Rk1 has a mass content of 25% to 60%
- the total mass of the ginsenoside Rg5 and the ginsenoside Rkl The content is above 70%
- the ginsenoside Rg5 has a mass content of 35% to 50%
- the ginsenoside Rk1 has a mass content of 35% to 50%
- the total mass of the ginsenoside Rg5 and the ginsenoside Rkl The content is above 80%;
- the mass ratio of the ginsenoside Rg5 and the ginsenoside Rkl is 0.8 to 1.2, and the total mass content of the ginsenoside Rg5 and the ginsenoside Rkl is 80% or more; Further preferably, the mass ratio of the ginsenoside Rg5 to the ginsenoside Rk1 is 0.8-1.2, and the total mass content of the ginsenoside Rg5 and the ginsenoside Rkl is 90% or more;
- the mass ratio of the ginsenoside Rg5 to the ginsenoside Rk1 is 1: 1, and the total mass content of the ginsenoside Rg5 and the ginsenoside Rk1 is 95% or more.
- the saponin nanomicelle comprising ginsenoside Rg5 and ginsenoside Rkl, the ginsenoside Rg5 having a molar content of 15% or more, the ginsenoside Rkl having a molar content of 15% or more, and the The total molar content of ginsenoside Rg5 and ginsenoside Rkl is above 50%.
- the ginsenoside Rg5 has a molar content of 25% or more
- the ginsenoside Rk1 has a molar content of 25% or more
- the total molar content of the ginsenoside Rg5 and the ginsenoside Rk1 is 80%. %the above;
- the ginsenoside Rg5 has a molar content of 25% to 60%
- the ginsenoside Rk1 has a molar content of 25% to 60%
- the total molar ratio of the ginsenoside Rg5 and the ginsenoside Rk1 The content is above 70%;
- the ginsenoside Rg5 has a molar content of 35% to 50%
- the ginsenoside Rk1 has a molar content of 35% to 50%
- the total molar amount of the ginsenoside Rg5 and the ginsenoside Rk1 The content is above 80%;
- the molar ratio of the ginsenoside Rg5 to the ginsenoside Rkl is 0.8 to 1.2, and the total molar content of the ginsenoside Rg5 and the ginsenoside Rkl is 80% or more;
- the molar ratio of the ginsenoside Rg5 to the ginsenoside Rkl is 0.8-1.2, and the total molar content of the ginsenoside Rg5 and the ginsenoside Rkl is above 90%;
- the molar ratio of the ginsenoside Rg5 to the ginsenoside Rk1 is 1: 1, and the total molar content of the ginsenoside Rg5 and the ginsenoside Rk1 is 95% or more.
- the remaining components are other types of saponins.
- the B-type saponin and any of the ginsenosides of the C-type saponin which are hydrophilic groups and are -11 or -OH can also form saponin nanometers. Positive micelles.
- the saponin nanomicelle which is a Rk4/Rg6 type ginsenoside nano reverse micelle, comprising ginsenoside Rk4 and ginsenoside Rg6, the mass content of the ginsenoside Rk4 Above 15%, the mass content of the ginsenoside Rg6 is 15% or more, and the total mass content of the ginsenoside Rk4 and the ginsenoside Rg6 is 50% or more.
- the ginsenoside Rk4 has a mass content of 25% to 60%
- the ginsenoside Rg6 has a mass content of 25% to 60%
- the total mass of the ginsenoside Rk4 and the ginsenoside Rg6 The content is above 70%;
- the ginsenoside Rk4 has a mass content of 35% to 50%
- the ginsenoside Rg6 has a mass content of 35% to 50%
- the total mass of the ginsenoside Rk4 and the ginsenoside Rg6 The content is above 80%;
- the mass ratio of the ginsenoside Rk4 to the ginsenoside Rg6 is 0.8 to 1.2, and the total mass content of the ginsenoside Rk4 and the ginsenoside Rg6 is 90% or more;
- the mass ratio of the ginsenoside Rk4 to the ginsenoside Rg6 is 1:1, and the total mass content of the ginsenoside Rk4 and the ginsenoside Rg6 is 95% or more.
- the saponin nanomicelle comprises ginsenoside Rk4 and ginsenoside Rg6, the ginsenoside Rk4 has a molar content of 15% or more, the ginsenoside Rg6 has a molar content of 15% or more, and the ginseng The total molar content of saponin Rk4 and ginsenoside Rg6 is 50% or more.
- the ginsenoside Rk4 has a molar content of 25% to 60%
- the ginsenoside Rg6 has a molar content of 25% to 60%
- the total molar amount of the ginsenoside Rk4 and the ginsenoside Rg6 The content is above 70%;
- the ginsenoside Rk4 has a molar content of 35% to 50%
- the ginsenoside Rg6 has a molar content of 35% to 50%
- the total molar amount of the ginsenoside Rk4 and the ginsenoside Rg6 The content is above 80%;
- the molar ratio of the ginsenoside Rk4 to the ginsenoside Rg6 is 0.8 to 1.2, and the total molar content of the ginsenoside Rk4 and the ginsenoside Rg6 is 90% or more;
- the molar ratio of the ginsenoside Rk4 to the ginsenoside Rg6 is 1:1, and the total molar content of the ginsenoside Rk4 and the ginsenoside Rg6 is 95% or more.
- the remaining components are other kinds of saponins.
- ginsenoside Rk4 and ginsenoside Rg6 either of the type B saponin and the ginsenoside of the type C saponin or -OH and being a hydrophilic group can form a saponin nano reverse micelle.
- the saponin nanomicelle which is a Rg3/Rg5/Rkl type ginsenoside nanopositive micelle, comprising ginsenoside Rg3, ginsenoside Rg5 and ginsenoside Rkl
- the ginsenoside Rg3 has a mass content of 15% to 45%
- the ginsenoside Rg5 has a mass content of 15% to 45%
- the ginsenoside Rk1 has a mass content of 15% to 45%
- the ginsenoside Rg3 The total mass content of the ginsenoside Rg5 and the ginsenoside Rkl is 70% or more.
- the ginsenoside Rg3 has a mass content of 15% to 25%
- the ginsenoside Rg5 has a mass content of 35% to 45%
- the ginsenoside Rkl has a mass content of 15% to 25%.
- the total mass content of the ginsenoside Rg3, the ginsenoside Rg5 and the ginsenoside Rkl is above 80%;
- the mass ratio of the ginsenoside Rg3, the ginsenoside Rg5 and the ginsenoside Rk1 is (0.8 to 1.2): (1.8-2.2): (0.8 to 1.2), and the ginsenoside Rg3,
- the total mass content of the ginsenoside Rg5 and the ginsenoside Rkl is 90%;
- the ginsenoside Rg3, the ginsenoside Rg5 and the ginsenoside Rkl The mass ratio is 1:2:1.
- the saponin nanomicelle comprises ginsenoside Rg3, ginsenoside Rg5 and ginsenoside Rkl
- the ginsenoside Rg3 has a molar content of 15% to 45%
- the ginsenoside Rg5 has a molar content of 15%.
- the molar content of the ginsenoside Rk1 is 15% to 45%
- the total molar content of the ginsenoside Rg3, the ginsenoside Rg5 and the ginsenoside Rk1 is 70% or more.
- the ginsenoside Rg3 has a molar content of 15% to 25%
- the ginsenoside Rg5 has a molar content of 35% to 45%
- the ginsenoside Rkl has a molar content of 15% to 25%.
- the total molar content of the ginsenoside Rg3, the ginsenoside Rg5 and the ginsenoside Rkl is above 80%;
- the molar ratio of the ginsenoside Rg3, the ginsenoside Rg5 and the ginsenoside Rk1 is (0.8 to 1.2): (1.8-2.2): (0.8 to 1.2), and the ginsenoside Rg3,
- the total molar content of the ginsenoside Rg5 and the ginsenoside Rkl is 90%;
- the molar ratio of the ginsenoside Rg3, the ginsenoside Rg5 and the ginsenoside Rkl is 1:2:1.
- the remaining components are other kinds of saponins.
- the saponin nanomicelle is a Rh2/Rh3/Rk2 type ginsenoside nanopositive micelle comprising ginsenoside Rh2, ginsenoside Rh3 and ginsenoside Rk2,
- the mass content of the ginsenoside Rh2 is 15% to 45%
- the mass content of the ginsenoside Rh3 is 15% to 45%
- the mass content of the ginsenoside Rk2 is 15% to 45%
- the ginsenoside Rh2 is The total mass content of the ginsenoside Rh3 and the ginsenoside Rk2 is 70% or more.
- the ginsenoside Rh2 has a mass content of 15% to 25%
- the ginsenoside Rh3 has a mass content of 35% to 45%
- the ginsenoside Rk2 has a mass content of 15% to 25%.
- the ginsenoside Rh2, the ginsenoside Rh3, and the ginsenoside Rk2 The total mass content is above 80%;
- the mass ratio of the ginsenoside Rh2, the ginsenoside Rh3, and the ginsenoside Rk2 is (0.8 to 1.2): (1.8-2.2): (0.8 to 1.2), and the ginsenoside Rh2
- the total mass content of the ginsenoside Rh3 and the ginsenoside Rk2 is above 90%;
- the mass ratio of the ginsenoside Rh2, the ginsenoside Rh3 and the ginsenoside Rk2 is 1:2:1.
- the saponin nanomicelle comprises ginsenoside Rh2, ginsenoside Rh3 and ginsenoside Rk2, the ginsenoside Rh2 has a molar content of 15% to 45%, and the ginsenoside Rh3 has a molar content of 15%. ⁇ 45%, the molar content of the ginsenoside Rk2 is 15% to 45%, and the total molar content of the ginsenoside Rh2, the ginsenoside Rh3 and the ginsenoside Rk2 is 70% or more.
- the ginsenoside Rh2 has a molar content of 15% to 25%
- the ginsenoside Rh3 has a molar content of 35% to 45%
- the ginsenoside Rk2 has a molar content of 15% to 25%.
- the total molar content of the ginsenoside Rh2, the ginsenoside Rh3 and the ginsenoside Rk2 is above 80%;
- the molar ratio of the ginsenoside Rh2, the ginsenoside Rh3 and the ginsenoside Rk2 is (0.8 to 1.2): (1.8-2.2): (0.8 to 1.2), and the ginsenoside Rh2
- the total molar content of the ginsenoside Rh3 and the ginsenoside Rk2 is above 90%;
- the molar ratio of the ginsenoside Rh2, the ginsenoside Rh3 and the ginsenoside Rk2 is 1:2:1.
- the other components are other kinds of saponins.
- the saponin nanomicelle which is a Rg2/Rk4/Rg6 type ginsenoside nanomicelle, comprising ginsenoside Rg2, ginsenoside Rk4 and ginsenoside Rg6, the ginseng
- the saponin Rg2 has a mass content of 15% to 45%
- the ginsenoside Rk4 has a mass content of 15% to 45%
- the ginsenoside Rg6 has a mass content of 15% to 45%
- the ginsenoside Rg2 the ginsenoside Rk4 and the ginsenoside Rg6 have a total mass content of 70% or more.
- the ginsenoside Rg2 has a mass content of 15% to 25%
- the ginsenoside Rk4 has a mass content of 35% to 45%
- the ginsenoside Rg6 has a mass content of 15% to 25%.
- the total mass content of the ginsenoside Rg2, the ginsenoside Rk4 and the ginsenoside Rg6 is above 80%;
- the mass ratio of the ginsenoside Rg2, the ginsenoside Rk4 and the ginsenoside Rg6 is (0.8 to 1.2): (1.8-2.2): (0.8 to 1.2), and the ginsenoside Rg2
- the total mass content of the ginsenoside Rk4 and the ginsenoside Rg6 is above 90%;
- the mass ratio of the ginsenoside Rg2, the ginsenoside Rk4 and the ginsenoside Rg6 is 1:2:1, and the ginsenoside Rg2, the ginsenoside Rk4 and the ginsenoside Rg6 are The total mass content is above 95%.
- the saponin nanomicelle comprises ginsenoside Rg2, ginsenoside Rk4 and ginsenoside Rg6, the ginsenoside Rg2 has a molar content of 15% to 45%, and the ginsenoside Rk4 has a molar content of 15%. ⁇ 45%, the ginsenoside Rg6 has a molar content of 15% to 45%, and the total molar content of the ginsenoside Rg2, the ginsenoside Rk4 and the ginsenoside Rg6 is 70% or more.
- the ginsenoside Rg2 has a molar content of 15% to 25%
- the ginsenoside Rk4 has a molar content of 35% to 45%
- the ginsenoside Rg6 has a molar content of 15% to 25%.
- the total molar content of the ginsenoside Rg2, the ginsenoside Rk4 and the ginsenoside Rg6 is above 80%;
- the molar ratio of the ginsenoside Rg2, the ginsenoside Rk4 and the ginsenoside Rg6 is (0.8 to 1.2): (1.8-2.2): (0.8 to 1.2), and the ginsenoside Rg2
- the total molar content of the ginsenoside Rk4 and the ginsenoside Rg6 is above 90%;
- the molar ratio of the ginsenoside Rg2, the ginsenoside Rk4 and the ginsenoside Rg6 is 1:2:1, and the ginsenoside Rg2, the ginsenoside Rk4 and the ginsenoside Rg6
- the total molar content is above 95%.
- the other components are other kinds of saponins except for the ginsenoside Rg2, the ginsenoside Rk4, and the ginsenoside Rg6.
- the Rg2/Rk4/Rg6 type ginsenoside nanomicelle is a Rg2/Rk4/Rg6 type ginsenoside nano reverse micelle.
- the Rg2/Rk4/Rg6 type ginsenoside nanomicelle contains a saponin of the formula 1 which forms a positive micelle, for example, it contains a trace amount of ginsenoside Rg3, ginsenoside Rg5 and ginseng.
- the Rg2/Rk4/Rg6 type ginsenoside nanomicelle is a Rg2/Rk4/Rg6 type ginsenoside nanopositive micelle.
- the saponin nanomicelle is a HSE-type ginsenoside nano-negative micelle comprising ginsenoside Rg2, ginsenoside Rg3, ginsenoside Rhl, ginsenoside Rg5, ginsenoside Rk4, ginsenoside Rh4, ginsenoside Rkl, ginsenoside Rg6 and ginsenoside Rk3, wherein the total mass content of the ginsenoside Rg2, ginsenoside Rg3 and ginsenoside Rhl is 15% to 45%, the ginsenoside Rg5, The total mass content of ginsenoside Rk4 and ginsenoside Rh4 is 15% to 45%, and the total mass content of the ginsenoside Rk1, ginsenoside Rg6 and ginsenoside Rk3 is 15% to 45%, and the ginsenoside Rg2, ginseng The total mass content of saponin Rg3, ginsenoside Rhl,
- the total mass content of the ginsenoside Rg2, the ginsenoside Rg3 and the ginsenoside Rhl is 15% to 25%, and the total mass content of the ginsenoside Rg5, the ginsenoside Rk4 and the ginsenoside Rh4 is 35%.
- the total mass content of the ginsenoside Rk1, ginsenoside Rg6 and ginsenoside Rk3 is 15% to 25%, and the ginsenoside Rg2, ginsenoside Rg3, ginsenoside Rhl, ginsenoside Rg5, ginsenoside Rk4 , the total mass content of ginsenoside Rh4, ginsenoside Rkl, ginsenoside Rg6 and ginsenoside Rk3 is above 80%;
- the total mass of the ginsenoside Rg2, ginsenoside Rg3 and ginsenoside Rhl, the total mass of the ginsenoside Rg5, ginsenoside Rk4 and ginsenoside Rh4, and the ginsenoside Rkl, ginsenoside Rg6 and ginseng The mass ratio between the total mass of saponin Rk3 is (0.8 to 1.2): (1.8-2.2): (0.8 ⁇ 1.2), and the ginsenoside Rg2, ginsenoside Rg3, ginsenoside Rhl, ginsenoside Rg5, ginsenoside Rk4, ginsenoside Rh4, ginsenoside Rkl, ginsenoside Rg6 and ginsenoside Rk3
- the total mass content is above 95%;
- the total mass of the ginsenoside Rg2, ginsenoside Rg3 and ginsenoside Rhl, the total mass of the ginsenoside Rg5, ginsenoside Rk4 and ginsenoside Rh4, and the ginsenoside Rkl, ginsenoside Rg6 and ginseng The mass ratio between the total mass of saponin Rk3 is 1:2:1.
- the saponin nanomicelle comprises ginsenoside Rg2, ginsenoside Rg3, ginsenoside Rhl, ginsenoside Rg5, ginsenoside Rk4, ginsenoside Rh4, ginsenoside Rk1, ginsenoside Rg6 and ginsenoside Rk3, wherein The total molar content of the ginsenoside Rg2, the ginsenoside Rg3 and the ginsenoside Rhl is 15% to 45%, and the total molar content of the ginsenoside Rg5, the ginsenoside Rk4 and the ginsenoside Rh4 is 15% to 45%, The total molar content of ginsenoside Rkl, ginsenoside Rg6 and ginsenoside Rk3 is 15% to 45%, and the ginsenoside Rg2, ginsenoside Rg3, ginsenoside Rhl, ginsenoside Rg5, ginsenoside Rk4, ginsenoside Rh4,
- the total molar content of the ginsenoside Rg2, the ginsenoside Rg3 and the ginsenoside Rhl is 15% to 25%, and the total molar content of the ginsenoside Rg5, the ginsenoside Rk4 and the ginsenoside Rh4 is 35%.
- the total molar content of the ginsenoside Rkl, ginsenoside Rg6 and ginsenoside Rk3 is 15% to 25%, and the ginsenoside Rg2, ginsenoside Rg3, ginsenoside Rhl, ginsenoside Rg5, ginsenoside Rk4 , the total molar content of ginsenoside Rh4, ginsenoside Rkl, ginsenoside Rg6 and ginsenoside Rk3 is above 80%;
- the total molar amount of the ginsenoside Rg2, the ginsenoside Rg3 and the ginsenoside Rhl, the total molar amount of the ginsenoside Rg5, the ginsenoside Rk4 and the ginsenoside Rh4, and the ginsenoside Rkl, ginsenoside Rg6 The molar ratio between the total molar amount of ginsenoside Rk3 and
- the total molar content of saponin Rg6 and ginsenoside Rk3 is above 95%; Most preferably, the total molar amount of the ginsenoside Rg2, ginsenoside Rg3 and ginsenoside Rhl, the total molar amount of the ginsenoside Rg5, ginsenoside Rk4 and ginsenoside Rh4, and the ginsenoside Rkl, ginsenoside Rg6
- the molar ratio between the total molar amount of ginsenoside Rk3 and the ginsenoside Rk3 is 1:2:1.
- ginsenoside Rg2 in addition to ginsenoside Rg2, ginsenoside Rg3, ginsenoside Rhl, ginsenoside Rg5, ginsenoside Rk4, ginsenoside Rh4, ginsenoside Rk1, ginsenoside Rg6 and ginsenoside Rk3, the remaining components All are other kinds of saponins.
- the present invention also provides a process for producing a saponin nanomicelle comprising the steps of: mixing the saponin of the formula 1 with an organic solvent capable of dissolving the saponin, and then removing the organic solvent.
- the organic solvent capable of dissolving saponin may be an organic solvent conventionally used in the art for dissolving ginsenosides and/or notoginsenosides, preferably methanol, ethanol, hydrazine, hydrazine-dimethylformamide (DMF). And one or more of n-butanol, propanol, tetrahydrofuran and pyridine.
- the method and conditions of the mixing may be the methods and conditions conventional in the art, which are based on the uniformity of mixing.
- the temperature of the mixing is preferably from 30 ° C to 80 ° C.
- the method and conditions for removing the organic solvent can be the methods and conditions conventional in the art.
- the organic solvent is preferably removed by concentration and concentration under reduced pressure at 30 ° C to 80 ° C. More preferably, the organic solvent is removed: after the concentrated drying under reduced pressure, vacuum drying is carried out at 30 ° C to 80 ° C until the loss on drying is less than 3% by mass.
- the invention also provides a preparation method of saponin nano micelle, which comprises the following steps:
- the reaction solution containing the saponin mixture obtained in the step (1) is purified to remove impurities, and then mixed with an organic solvent capable of dissolving the saponin to remove the organic solvent, thereby obtaining a saponin nanomicelle;
- reaction mixture containing the saponin mixture obtained in the step (1) is purified and separated, various saponin monomers are obtained, and one or more of the ginsenosides represented by the formula 1 are dissolved therein.
- the organic solvent of the saponin is mixed, and the organic solvent is removed to obtain a saponin nanomicelle.
- the Araliaceae plant extract is conventionally described in the art, and is generally an extract of one or more of roots, stems, leaves and fruits of the Araliaceae plant.
- the Araliaceae plant is preferably Chinese ginseng (Panax ginseng), Korean ginseng ⁇ . Sinensis J. W, American ginseng quique folius, Japanese ginseng (P. japonicus) ⁇ Vietnamese ginseng (P. réellenamensis) ⁇ pseudo ginseng P One or more of pseudogiengng and Sanqi P. notoginseng.
- the cucurbit plant extract is conventionally described in the art and is generally an extract of one or more of roots, stems, leaves and fruits of the cucurbitaceae.
- the Cucurbitaceae plant is preferably Gynostemma pentaphyllum.
- the Araliaceae plant extract and/or the Cucurbitaceae plant extract preferably satisfy the following conditions: the ginseng total saponin content percentage is 60%, preferably 80%, more preferably 90%; or Any one of the following ginsenoside compounds containing 60% by mass, preferably 80%, more preferably 90%: ginsenoside Rbl, ginsenoside Rb2, ginsenoside Rb3, ginsenoside Re, ginsenoside Rc, ginsenoside Rd, ginsenoside Rgl, ginsenoside Rg2, ginsenoside Rg3, ginsenoside Rhl, ginsenoside Rh2, ginsenoside Rh3, ginsenoside Fl, ginsenoside F2 and notoginsenoside Rl, further preferably ginsenoside Rbl, ginsenoside Re or ginseng Saponin F2.
- the Araliaceae plant extract and/or the Cucurbitaceae plant extract are either commercially available or obtained according to the
- the acidic aqueous solution may be conventionally described in the art, and the acidic substance in the acidic aqueous solution may be an organic acid and/or an inorganic acid, preferably citric acid, acetic acid, formic acid, oxalic acid, One or more of succinic acid, salicylic acid, tartaric acid, malic acid, citric acid, methanesulfonic acid, benzoic acid, hydrochloric acid, nitric acid, sulfuric acid and phosphoric acid, more preferably acetic acid and/or citric acid.
- the pH of the acidic aqueous solution is preferably 6.5, and further preferably, the pH is adjusted to 6.5 with acetic acid and/or citric acid; more preferably, the pH of the acidic aqueous solution is 3, The pH is preferably adjusted to 3 with acetic acid and/or citric acid.
- the conditions of the acid hydrolysis reaction may be conventional conditions in the art.
- the acid The temperature at which the reaction is carried out is preferably from 60 ° C to 100 ° C, more preferably from 80 ° C to 90 ° C.
- the acid hydrolysis reaction time is preferably from 2 hours to 48 hours, more preferably from 3 hours to 6 hours.
- the method for purifying and removing impurities may be conventionally described in the art, and only the impurities other than the saponin mixture in the reaction solution containing the saponin mixture in the step (1) may be removed.
- the method for purifying and removing impurities is the following method 1 or method 2;
- Method one includes the following steps:
- step (b) adjusting the pH of the reaction solution after the step (a) to a basic condition with a base to obtain a precipitate;
- step (d) Cool the saponin mixture in step (c) to below 5 °C, remove the precipitate, and then dry.
- the cooling and the standing are conventional operations in the art, and the cooling is preferably cooled to -20 ° C to 30 ° C, and the standing time is preferably 4 hours or longer.
- the precipitation removal is conventional in the art and is typically filtration or centrifugation.
- the base is conventional in the art and may be an organic base and/or an inorganic base;
- the organic base is preferably sodium methoxide, sodium ethoxide, potassium acetate, sodium acetate, triethylamine, One or more of ammonia water, methanolamine, potassium t-butoxide and sodium t-butoxide, preferably sodium hydroxide, potassium hydroxide, calcium hydroxide, potassium carbonate, sodium carbonate, carbonic acid
- potassium hydrogen and sodium hydrogencarbonate more preferably sodium carbonate and/or sodium hydrogencarbonate.
- the concentration of the base in the reaction liquid is preferably 0.05 mol/L to 1 mol/L.
- the pH adjustment to alkaline is preferably adjusted to a pH of from 8 to 14.
- the precipitate is preferably dried as conventionally in the art, and then subjected to the step (c), the drying is: drying at 30 ° C to 80 ° C until the loss on drying is lower than the mass The percentage is 5%.
- the amount of the organic solvent used is conventional in the art, preferably the amount of the precipitate dissolved, more preferably the volume ratio of the precipitate to the organic solvent is ( 1: 1) ⁇ (1:5).
- the mixing temperature is preferably from 30 ° C to 80 ° C.
- the cooling temperature is preferably -20 ° C to 5 ° C.
- the precipitation removal is a routine operation in the art, and generally filtration is sufficient.
- the manner of drying can be conventional in the art, preferably concentrated under reduced pressure.
- the method 2 includes the following steps:
- reaction mixture of the saponin-containing mixture obtained in the step (1) is adjusted to a pH of 8 to 14 with a base, and the solution A is obtained after precipitation;
- step S1 the base is as described in the aforementioned step (b).
- the number of extractions may be conventional in the art, preferably 1 to 5 times.
- the volume of the n-butanol and the solution A is preferably (1:0.5) to (1:4).
- the n-butanol and the water-washing water preferably have a volume of (1:0.5) to (1:4).
- the operation of removing the solvent in the n-butanol layer may be conventional in the art, preferably concentrated under reduced pressure.
- the purification separation method and conditions may be a conventional method and conditions in the art, preferably column chromatography separation.
- the saponin monomer is ginsenoside Rg2, ginsenoside Rg3, ginsenoside Rg4, ginsenoside Rg5, ginsenoside Rg6, ginsenoside Rhl, ginsenoside Rh2, ginsenoside Rh3, ginsenoside Rh4, ginseng
- saponin Rf ginsenoside Rs3, ginsenoside Rkl, ginsenoside Rk2, ginsenoside Rk3, ginsenoside Rk4, ginsenoside, ginsenoside F4, notoginsenoside R2 and notoginsenoside T5.
- the organic solvent capable of dissolving the saponin is preferably one of methanol, ethanol, hydrazine, hydrazine-dimethylformamide (DMF), n-butanol, propanol, tetrahydrofuran and pyridine. Or a variety.
- the mixing is a routine operation in the art, and the mixing is uniform.
- the temperature of the mixing is preferably from 30 ° C to 80 ° C.
- the method for removing the organic solvent may be conventional in the art, and is preferably concentrated and dried under reduced pressure at 30 ° C to 80 ° C; more preferably: after concentration and drying under reduced pressure at 30 ° C. Vacuum drying was carried out at 80 ° C until the loss on drying was less than 3% by mass.
- the preparation method of the saponin nanomicelle comprises the following steps:
- the concentrate obtained in the step (3') is dried to obtain a saponin nanomicelle; wherein the saponin described in the step () is any one of the following saponin compounds: ginseng total saponin Ra0, ginseng Total saponin Ral, ginseng total saponin Ra2, ginseng total saponin Ra3, ginsenoside Rbl, ginsenoside Malonyl-Rbl, ginsenoside Rb2, ginsenoside Malonyl-Rb2, ginsenoside Rb3, ginsenoside Malonyl-Rb3, ginsenoside Rgl, ginsenoside Malonyl-Rgl, ginsenoside Rc, ginsenoside Malonyl-Rc, ginsenoside F2, ginsenoside Re, ginsenoside Rd, ginsenoside Malonyl-Rd, ginsenoside Rl, ginsenoside Rsl, ginsenoside Rsl, ginsen
- the saponin nanomicelle is HSE-type ginsenoside nano-nose micelle; when the saponin is ginsenoside Rbl, the saponin nanomicelle is Rg3 type saponin nano positive micelle; when the saponin is ginsenoside F2, the saponin nanomicelle is Rh2 type ginsenoside nano positive micelle; when the saponin is ginsenoside Re, the saponin
- the nanomicelle is a Rg2 type ginsenoside nano reverse micelle.
- the method for preparing the saponin nanomicelle comprises the following steps:
- reaction liquid obtained by the reaction of the step (1 ⁇ ) is cooled to 15 ° C ⁇ 30 ° C, and then neutralized with Na 2 CO 3 , after precipitation to obtain a solution A;
- the solid obtained in the step (4 ⁇ ) is mixed with absolute ethanol, then cooled to below 5 ° C, allowed to stand for 4 to 24 hours, and the precipitate is removed, followed by concentration under reduced pressure to obtain a concentrated Repeating the above operation of the step (5 ⁇ ) 1 ⁇ 3 times;
- the concentrate obtained in the step (5 ⁇ ) is dried to obtain a saponin nanomicelle;
- the saponin described in the step (1 ⁇ ) is any one of the following saponin compounds: ginseng total saponin Ra0, ginseng total Saponin Ral, ginseng total saponin Ra2, ginseng total saponin Ra3, ginsenoside Rbl, ginsenoside Malonyl-Rbl, ginsenoside Rb2, ginsenoside Malonyl-Rb2, ginsenoside Rb3, ginsenoside Malonyl-Rb3, ginsenoside Rgl, ginsenoside Malony -Rgl, ginsenoside Rc, ginsenoside Malonyl-Rc, ginsenoside F2, ginsenoside Re, ginsenoside Rd, ginsenoside Malonyl-Rd, ginsenoside Rl, ginsenoside Rsl, ginsenoside Rs2, notogins
- the saponin nanomicelle is HSE-type ginsenoside nano-nose micelle; when the saponin is ginsenoside Rbl, the saponin nanomicelle is Rg3 ginsenoside Nano saponin; when the saponin is ginsenoside F2, the saponin nanomicelle is Rh2 type ginsenoside nanopositive micelle; when the saponin is ginsenoside Re, the saponin nanomicelle It is a Rg2 type ginsenoside nano anti-micelle.
- the present invention also provides a saponin nanomicelle produced by the preparation method as described above.
- the invention also provides a preparation method of a saponin nano-positive micelle, which comprises the steps of: mixing a saponin nano reverse micelle, an organic solvent capable of dissolving saponin and a seed crystal of a saponin nano-nano micelle to remove an organic solvent, That is, wherein the seed crystal of the saponin nano-positive micelle is: one or more of the saponins of the formula 1 which is -11 or -OH, and is a hydrophilic group;
- the saponin nano reverse micelles are one or more of the saponin nano reverse micelles prepared by the aforementioned preparation method and any of the saponin nano reverse micelles as described above.
- the seed crystal of the saponin nano-positive micelle is preferably a glycosyl group or a modified sugar group, more preferably a better, specific group of the above-mentioned groups other than -H and -OH Any of the others.
- the seed crystal of the saponin nanopositive micelle is preferably one or more of ginsenoside Rg3, ginsenoside Rg5 and ginsenoside Rkl.
- the saponin nano reverse micelle is any saponin nano reverse micelle which can be obtained according to the preparation method of the present invention and/or any saponin nano reverse micelle as described above, preferably Rg2 /Rk4/Rg6 type ginsenoside nano anti-micelle.
- the organic solvent capable of dissolving saponin may be an organic solvent conventionally used in the art for dissolving ginsenosides and/or notoginsenosides, preferably methanol, ethanol, hydrazine, hydrazine-dimethylformamide (DMF). And one or more of n-butanol, propanol, tetrahydrofuran and pyridine.
- the method and conditions of the mixing may be conventional methods and conditions in the art, Evenly.
- the temperature of the mixing is preferably from 30 ° C to 80 ° C.
- the method and conditions for removing the organic solvent can be the methods and conditions conventional in the art.
- the organic solvent is preferably removed by concentration and concentration under reduced pressure at 30 ° C to 80 ° C. More preferably, the organic solvent is removed: after the concentrated drying under reduced pressure, vacuum drying is carried out at 30 ° C to 80 ° C until the loss on drying is less than 3% by mass.
- the present invention also provides a saponin nanopositive micelle obtained by the preparation method as described above.
- the present invention also provides the use of a saponin nanomicelle as described above as an aqueous co-solvent or a pharmaceutical carrier for a liposoluble compound or composition, said saponin nanomicelle being a saponin nanopositive micelle.
- the fat-soluble compound or composition may be a fat-soluble compound conventional in the art, preferably soybean isoflavone, cardamom, resveratrol, coenzyme Q10, vitamin A, vitamin D, vitamin E, One or more of vitamin K, ginkgo extract, melatonin, lycopene and beta-carotene.
- the mass of the fat-soluble compound or composition and the saponin nano-nose micelles is preferably (1:1) to (15:1), more preferably 1:9.
- the above aqueous auxiliary solvent means a cosolvent capable of increasing the solubility of a substance which is hardly soluble in water in an aqueous solution system.
- the present invention also provides the use of a saponin nanomicelle as described above for the preparation of a pharmaceutical preparation, a health care product or a cosmetic of a poorly water-soluble drug, wherein the saponin nanomicelle is a saponin nanopositive micelle.
- the poorly water-soluble drug may be a water-insoluble drug conventional in the art, preferably paclitaxel, docetaxel, cabazitaxel, irinotecan hydrochloride, topotecan hydrochloride, hydroxy Camptothecin, minoxidil, azithromycin, epirubicin hydrochloride, doxorubicin hydrochloride, amrubicin hydrochloride, tacrolimus, fluorouracil, vincristine sulfate, vinblastine sulfate, vindesine sulfate, Vinorelbine tartrate, huperzine A, homoharringtonine, harringtonine, epothilone, epothilone oxime, epothilone (e, epothilone 0, epothilone) , epothilone?, bortezomib, etoposide phosphate, gemcitabine hydrochloride, fludarabine phosphate,
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the saponin nanomicelle as described above and the poorly water-soluble drug; the saponin nanomicelle is a saponin nanopositive micelle.
- the quality of the poorly water-soluble drug and the saponin nanopositive micelle is preferably (1:3) to (1:12), more preferably 1:6.
- the invention further provides the use of a saponin nanomicelle as described above as a lipid cosolvent or a pharmaceutical carrier for a water soluble compound or composition, said saponin nanomicelle being a saponin nano reverse micelle.
- the water-soluble compound or composition may be a conventional water-soluble compound in the art, preferably a peptide, a polypeptide, a protein, a nucleic acid (DNA or RNA (preferably RNAi) or a fragment thereof), insulin, erythropoiesis , leptin, growth factor, growth hormone releasing hormone, colony stimulating factor, water soluble hormone (parathyroid hormone or its fragment or analog), luteinizing hormone releasing hormone (LHRH) and its analogues (eg, narfare Lin, buserelin, goserelin, interferon, cytokines, polysaccharides (eg, heparin), heparin compounds, DNA, RNA fragments and their plasmids, RNA interference agents, and their immunizing agents and vaccines One or more.
- the water-soluble compound or composition and the saponin nano reverse micelle preferably have a mass of (1:1) to (15:1), more preferably 1:9.
- the above-mentioned fat cosolvent means: a cosolvent capable of increasing the solubility of a substance which is hardly soluble in fat in an oil or fat system.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the saponin nanomicelle as described above and the water soluble compound or composition; the saponin nanomicelle is a saponin nano reverse micelle.
- the quality of the water-soluble compound or composition and the saponin nano reverse micelle is preferably (1:1) ⁇ (15: 1), more preferably 1:9.
- the reagents and starting materials used in the present invention are commercially available.
- the positive effects of the present invention are: 1.
- the saponin nanomicelle of the present invention is the first one, wherein the positive micelle is applied to a fat-soluble component in foods, health care products, cosmetics, etc., so that the fat-soluble component is dissolved in water or alcohol to achieve nanocrystallization. It plays an important role in the application range of commodity development; and, in actual use, the relevant components are transported to the site of action, hydrolyzed under physiological conditions, released, exerting efficacy or effect, and wherein ginsenosides and/or notoginsenosides It also exerts a therapeutic effect or a beneficial effect.
- the saponin nanomicelle of the invention is used as a drug carrier or applied to a medicine, and the micelle encapsulates a pharmaceutically active ingredient which is hardly soluble in water, has a stronger drug-loading capacity, higher biocompatibility, and has a drug loading of at least 99.5%.
- the drug-loaded micelles are placed in the glucose solution for more than 10 hours, and the encapsulation efficiency is still not less than 90%.
- As a medium for the drug component it can replace the existing drug carrier such as pharmaceutical cosolvent or polymer micelle.
- reverse micelles can be used as cosolvents or combination preparations for water-soluble drugs or water-soluble ingredients, and can also be used as drug-loading drugs for water-soluble drugs or ingredients.
- Micellar can be used as cosolvents or combination preparations for water-soluble drugs or water-soluble ingredients, and can also be used as drug-loading drugs for water-soluble drugs or ingredients.
- Fig. 1 is a graph showing the relationship of each component in the reactant of Example 2 with time.
- Fig. 2 is a graph showing the particle size distribution of the drug-loaded ginsenoside nanomicelles of Application Example 1.
- Fig. 3 is a photograph showing the drug-loaded micelle solution of the application examples 1 to 2 and their comparison.
- Fig. 4 is a graph showing the particle size distribution of the drug-loaded ginsenoside nanomicelles of the application example.
- Fig. 5 is a graph showing the particle size distribution of the drug-loaded ginsenoside nanomicelle of Application Example 8.
- Figure 6 is a photograph showing the resveratrol drug-loaded micelle solution of Application Example 12 and its comparison.
- Fig. 7 is a graph showing the particle size distribution of the ginsenoside nanomicelle of Example 1 in a 5% glucose solution.
- Fig. 8 is a graph showing the particle size distribution of the ginsenoside nanomicelle of Example 2 in a 5% glucose solution.
- Fig. 9 is a transmission electron micrograph of the HSE-type ginsenoside nanomicelle of Example 1.
- Fig. 10 is a transmission electron micrograph of the Rg3/Rg5/Rkl type ginsenoside nanomicelle of Example 2.
- Figure 11 is a transmission electron micrograph of the Rg2/Rk4/Rg6 type ginsenoside nano reverse micelle of Example 5.
- Figure 12 is a transmission electron micrograph of the paclitaxel-loaded ginsenoside nanomicelle of Application Example 1. detailed description
- ginseng total saponins are prepared; Porous adsorption resin method (for example, the method described in Chinese Patent No. CN201010527369.X)
- the ginsenoside is divided into a mixed saponin A mainly composed of ginsenoside Re and ginsenoside Rgl and mainly composed of ginsenoside Fl, ginsenoside Rg2, ginsenoside F2.
- a mixed saponin B composed of notoginsenoside Fe, ginsenoside Rd, ginsenoside Rb2, ginsenoside Rc, ginsenoside Rbl and ginsenoside Rb3, followed by recrystallization or alumina column chromatography to obtain a simpler ginsenoside Mixture (for example, the method described in Chinese invention patent CN200610093615.9), finally passed through the column
- the ginsenoside monomer was obtained by chromatography.
- the preparation method of the ginsenoside monomer used in the following examples is as follows:
- ginsenoside Rbl Preparation of ginsenoside Rbl, ginsenoside Rb3, ginsenoside Rd, ginsenoside Re and other monomers by using American ginseng root extract: 300 g of ginseng root saponin with a mass content of 81% was dissolved in 4 L of methanol, and after ultrasonic assisted dissolution, 6 L of purified water was added to prepare a ginsenoside sample solution of 40 v/v% methanol aqueous solution.
- the column was repeatedly subjected to preparation to obtain 500 g of 90% or more of ginsenoside Re, 500 g of 90% or more of ginsenoside Rb1, 500 g of 90% or more of ginsenoside Rb3, and 500 g of 90% or more of ginsenoside Rd.
- the precipitate was heated to 60 ° C with 1.0 L of absolute ethanol, and then allowed to stand at 4 ° C for 2 hours, and filtered with ⁇ . ⁇ filter paper to remove the precipitate, and the filtrate was concentrated under reduced pressure;
- the compressed concentrate was dissolved in 0.4 L of absolute ethanol, and then placed at a temperature of 4 ° C for 2 hours, filtered through a ⁇ . ⁇ filter paper, and concentrated under reduced pressure to obtain 153 g of HSE-type ginsenoside nanomicelle.
- HPLC analysis conditions were as follows: Column ZORBAX Eclipse XDB-C18 4.6x250mm; detection wavelength UV/Vis, 203mm; flow rate 1.0ml/min; column temperature 50°C; The system running time is 80 min; the mobile phase (gradient) is shown in Table 1 below.
- reaction solution obtained in the reaction of the step (1) was allowed to stand at room temperature to be cooled to 30 ° C, neutralized with 10 wt% of sodium carbonate, and then filtered through a 0.45 ⁇ filter paper to remove the precipitate to obtain a filtrate.
- the reaction mixture was analyzed by HPLC under the same conditions as described in Example 1.
- the mass percentage of each component in the reaction solution was as shown in Table 3 below and FIG. 1 under the conditions.
- the Rg3/Rg5/Rkl type ginsenoside nanomicelle prepared in this embodiment can replace the existing polyoxyethylene castor oil or Tween-80.
- Preparation method of ginsenoside nanomicelle of Rg3/Rg5/Rkl by using ginsenoside Rb3 100 g of ginsenoside Rb3 is placed in a reaction tank, and 38 g of Rg3/Rg5/Rkl type ginsenoside nanometer can be obtained by the same method as in Example 2. Micellar. The components of the analysis were analyzed by HPLC in the same manner as in Example 1, and the results are shown in Table 4 below.
- Preparation method of ginsenoside nanomicelle of Rg3/Rg5/Rkl type by using ginsenoside Rd 100g of ginsenoside Rd is placed in the reaction tank, and the method of the second embodiment can obtain 23g.
- Rg2/Rk4/Rg6 ginsenoside nano reverse micelle dissolve it in 200ml absolute ethanol, concentrate to 100ml under reduced pressure, add a small amount of Rg3/Rg5/Rkl micelle seed crystal, cool the crystal, consider, dry, That is, 5.4 g of Rg2/Rk4/Rg6 type ginsenoside nanopositive micelles were obtained.
- the raw material ginsenoside Re used in the present example, and the obtained Rg2/Rk4/Rg6 type ginsenoside nanopositive micelles were subjected to HPLC detection and analysis of the components of Example 1, and the results are shown in Table 7 below.
- the ginsenoside F2 is prepared by the following method:
- ginsenoside Rbl Take high-purity 200g ginsenoside Rbl into the reaction tank, add 500ml of purified water, add alpha-galactosidase, and digest the enzyme for 4 ⁇ 44 hours (more preferably 8 ⁇ 12 hours) at 30 °C. 200 ml of n-butanol was extracted 3 times, and n-butanol was combined, and concentrated under reduced pressure to obtain 136 g of ginsenoside F2.
- Example 10 In the same manner as in Example 8, an Rg5-rich fraction was obtained, which was concentrated by a nanofiltration membrane, extracted with n-butanol, concentrated under reduced pressure, and dried to obtain 8.6 g of an Rg5 monomer. Further, 8.6 g of the mixture was dissolved in 50 ml of anhydrous ethanol, and then concentrated to dryness by a reduced pressure to obtain 8.6 g of a ginsenoside nanomicelle of Rg5 type. The components of the analysis were analyzed by HPLC in the same manner as in Example 1, and the results are shown in Table 10 below.
- the Rk1 enrichment section was taken, concentrated by a nanofiltration membrane, extracted with n-butanol, concentrated under reduced pressure, and dried to obtain 2.6 g of Rkl monomer. Further, 2.6 g of the mixture was dissolved in 20 ml of anhydrous ethanol, and then concentrated under reduced pressure to dryness to obtain 2.6 g of ginsenoside nanomicelle of Rkl type.
- the analytical components were analyzed by HPLC in the same manner as in Example 1, and the results are shown in Table 11 below.
- Example 11 the Rk4 enrichment section was taken, concentrated by a nanofiltration membrane, extracted with n-butanol, concentrated under reduced pressure, and dried to obtain 3.3 g of Rk4 monomer. Further, 3.3 g of the mixture was dissolved in 20 ml of absolute ethanol, and then concentrated under reduced pressure to dryness to obtain 3.3 g of a ginsenoside nano reverse micelle of Rk4 type. The analysis components were analyzed by HPLC as in Example 1. The results are shown in Table 13 below. Table 13 Contents of Rk4 type ginsenoside nano-anti-micelle component of Example 12
- Example 11 In the same manner as in Example 11, an Rg6-rich fraction was obtained, concentrated by a nanofiltration membrane, extracted with n-butanol, concentrated under reduced pressure, and dried to obtain 3.0 g of an Rg6 monomer. Further, 3.0 g of the mixture was dissolved in 20 ml of absolute ethanol, and then concentrated under reduced pressure to dryness to obtain 3.0 g of a ginsenoside nano-anti-micelle of Rg6 type. The components of the analysis were analyzed by HPLC in the same manner as in Example 1, and the results are shown in Table 14 below.
- Paclitaxel 30 mg and 180 mg of the Rg3/Rg5/Rkl type ginsenoside nanomicelle of Example 2 were added to a 5 ml vial and 2.0 ml of absolute ethanol was added, followed by stirring with a vortex After the mixer is dissolved and filtered with 0.45 ⁇ filter paper, the paclitaxel micelle-encapsulated solution can be prepared. After the particle size distribution was examined, the results are shown in Fig. 2.
- the paclitaxel micelle-encapsulated solution was added to 75 ml of a commercially available glucose solution for injection, and the image after standing at room temperature for 12 hours is shown in Fig. 3B.
- a 30 mg paclitaxel injection of a commercially available Peking Union Pharmaceutical Factory was added to 75 ml.
- a commercially available glucose solution for injection was shown in Fig. 3D after standing at room temperature for 12 hours; it was apparent that the paclitaxel micelle solution was clear and transparent.
- the ginsenoside nanomicelle has a drug loading of at least 99.5%, and the obtained drug-loaded micelles are placed in the glucose solution for more than 10 hours, and the encapsulation efficiency is still not less than 90%.
- the drug and ginsenoside nanomicelles were prepared in the following combinations of paclitaxel micelle-encapsulating solutions: 10 mg and 30 mg, 10 mg and 120 mg or 10 mg and 60 mg.
- Paclitaxel 30 mg and 180 mg of the Rg5/Rkl type ginsenoside nano micelle of Example 8 were added to a 5 ml vial and 2.0 ml of absolute ethanol was added, and then dissolved in a vortex mixer and filtered through a 0.45 ⁇ filter paper. A paclitaxel micelle-encapsulated solution is prepared.
- the paclitaxel micelle-encapsulated solution was added to 75 ml of a commercially available glucose solution for injection, and allowed to stand at room temperature for 12 hours.
- a 30 mg paclitaxel injection of a commercially available Peking Union Pharmaceutical Factory was added to 75 ml of a commercially available glucose solution for injection, and the solution was allowed to stand at room temperature. After 12 hours; it can be clearly seen that the paclitaxel micelle solution is clear and transparent, while the comparative sample is turbid.
- the ginsenoside nanomicelle has a drug loading of at least 99.5%, and the obtained drug-loaded micelles are placed in the glucose solution for more than 10 hours, and the encapsulation efficiency is still not less than 90%.
- the drug and ginsenoside nanomicelles were prepared in the following combinations of paclitaxel micelle-encapsulating solutions: 10 mg and 30 mg, 10 mg and 120 mg or 10 mg and 60 mg.
- Paclitaxel and Rg5-loaded micelles Paclitaxel 30 mg and 180 mg of the Rg5 type ginsenoside nanomicelle of Example 9 were added to a 5 ml vial and 2.0 ml of absolute ethanol was added, and then dissolved in a vortex mixer and filtered through a 0.45 ⁇ filter paper to prepare a solution. The paclitaxel micelles encapsulate the solution.
- the paclitaxel micelle-encapsulated solution was added to 75 ml of a commercially available glucose solution for injection, and allowed to stand at room temperature for 12 hours.
- a 30 mg paclitaxel injection of a commercially available Peking Union Pharmaceutical Factory was added to 75 ml of a commercially available glucose solution for injection, and the solution was allowed to stand at room temperature. After 12 hours; it can be clearly seen that the paclitaxel micelle solution is clear and transparent, while the comparative sample is turbid.
- the ginsenoside nanomicelle has a drug loading of at least 99.5%, and the obtained drug-loaded micelles are placed in the glucose solution for more than 10 hours, and the encapsulation efficiency is still not less than 90%.
- the drug and ginsenoside nanomicelles were prepared in the following combinations of paclitaxel micelle-encapsulating solutions: 10 mg and 30 mg, 10 mg and 120 mg or 10 mg and 60 mg.
- Paclitaxel 30 mg and 180 mg of the Rh2 type ginsenoside nanomicelle of Example 7 were added to a 5 ml vial and 2.0 ml of absolute ethanol was added, and then dissolved in a vortex mixer and filtered through a 0.45 ⁇ filter paper to prepare a solution.
- the paclitaxel micelles encapsulate the solution.
- the paclitaxel micelle-encapsulated solution was added to 75 ml of a commercially available glucose solution for injection, and allowed to stand at room temperature for 12 hours.
- a 30 mg paclitaxel injection of a commercially available Peking Union Pharmaceutical Factory was added to 75 ml of a commercially available glucose solution for injection, and the solution was allowed to stand at room temperature. After 12 hours; it can be clearly seen that the paclitaxel micelle solution is clear and transparent, while the comparative sample is turbid.
- the ginsenoside nanomicelle has a drug loading of at least 99.5%, and the obtained drug-loaded micelles are placed in the glucose solution for more than 10 hours, and the encapsulation efficiency is still not less than 90%.
- the drug and ginsenoside nanomicelles were prepared in the following combinations of paclitaxel micelle-encapsulating solutions: 10 mg and 30 mg, 10 mg and 120 mg or 10 mg and 60 mg.
- Paclitaxel and Rg2/Rk4/Rg6 positive micelle-loaded micelles Paclitaxel 30 mg and 180 mg of the Rg2/Rk4/Rg6 type ginsenoside nano-nose micelle of Example 6 were added to a 5 ml vial and 2.0 ml of absolute ethanol was added, which was then dissolved in a vortex mixer and filtered through a 0.45 ⁇ filter paper. The paclitaxel micelle-encapsulating solution can be prepared.
- the paclitaxel micelle-encapsulated solution was added to 75 ml of a commercially available glucose solution for injection, and allowed to stand at room temperature for 12 hours.
- a 30 mg paclitaxel injection of a commercially available Peking Union Pharmaceutical Factory was added to 75 ml of a commercially available glucose solution for injection, and the solution was allowed to stand at room temperature. After 12 hours; it can be clearly seen that the paclitaxel micelle solution is clear and transparent, while the comparative sample is turbid.
- the ginsenoside nanomicelle has a drug loading of at least 99.5%, and the obtained drug-loaded micelles are placed in the glucose solution for more than 10 hours, and the encapsulation efficiency is still not less than 90%.
- the drug and ginsenoside nanomicelles were prepared in the following combinations of paclitaxel micelle-encapsulating solutions: 10 mg and 30 mg, 10 mg and 120 mg or 10 mg and 60 mg.
- docetaxel anhydrate Docetael.anhydrous
- 180 mg of Rg5/Rkl type ginsenoside nanomicelle of Example 8 were added to a 5 ml vial and 2.0 ml of absolute ethanol was added, followed by dissolution with a vortex mixer. After filtration of 0.45 ⁇ filter paper, a docetaxel anhydrate-free micelle-encapsulated solution can be prepared.
- the above docetaxel anhydrous micelle encapsulated solution was added to 75 ml of commercially available glucose solution for injection, and allowed to stand at room temperature for 12 hours; as a comparison, 20 mg of paclitaxel injection from a commercially available Shandong Qilu Pharmaceutical Factory was added to a commercially available injection of 75 ml.
- the glucose solution was allowed to stand at room temperature for 12 hours; it was apparent that the paclitaxel micelle solution was clear and transparent, and the comparative sample was cloudy.
- the ginsenoside nano-micelle has a drug loading of at least 99.5%, and the obtained drug-loaded micelles are placed in the glucose solution for more than 10 hours, and the encapsulation efficiency is still not less than 90%.
- a docetaxel anhydrate micelle-encapsulating solution having a mass of the drug and ginsenoside nanomicelles of the following combination was prepared: 10 mg and 30 mg, 10 mg and 120 mg or 10 mg and 60 mg.
- the above docetaxel anhydrous micelle encapsulated solution was added to 75 ml of commercially available glucose solution for injection, and the image after standing at room temperature for 12 hours is shown in Fig. 3A; as a comparison, Jiangsu Hengrui Pharmaceutical Co., Ltd. is commercially available.
- the company's 20mg docetaxel injection, adding 75ml of commercially available glucose solution for injection, the image after standing at room temperature for 12 hours is shown in Figure 3C; it can be clearly seen that the docetaxel anhydrate micelle solution is clear and transparent. , and the comparative sample is turbid.
- the ginsenoside nanomicelle has a drug loading of at least 99.5%, and the obtained drug-loaded micelles are placed in the glucose solution for more than 10 hours, and the encapsulation efficiency is still not less than 90%.
- a drug and ginsenoside nanomicelles having a mass of the following combination of docetaxel anhydrate micelle-encapsulated solution were prepared: 10 mg and 30 mg, 10 mg and 120 mg or 10 mg and 60 mg.
- Docetaxel trihydrate 20 mg and 120 mg of the Rh2 type ginsenoside nanomicelle of Example 7 were added to a 5 ml vial, and then 2.0 ml of absolute ethanol was added, dissolved in a vortex mixer, and filtered through a 0.45 ⁇ filter paper. Thereafter, a docetaxel trihydrate micelle-encapsulated solution is prepared. After the particle size distribution was examined, the results are shown in Fig. 5. After testing, the ginsenoside nanomicelle has a drug loading of at least 99.5%, and the obtained drug-loaded micelles are placed in the glucose solution for more than 10 hours, and the encapsulation efficiency is still not less than 90%.
- a docetaxel trihydrate micelle-encapsulating solution having the following combination of the drug and ginsenoside nanomicelles was prepared: 10 mg and 30 mg, 10 mg and 120 mg or 10 mg. With 60mg.
- Minoxidil and 120 mg of HSE-type ginsenoside nanomicelle of Example 1 were added to a 5 ml vial, and then 2.0 ml of absolute ethanol was added, dissolved in a vortex mixer, and then filtered through a 0.45 ⁇ m filter paper to prepare a solution.
- Minoxidil micelles encapsulate the solution.
- the ginsenoside nanomicelle has a drug loading of at least 99.5%, and the obtained drug-loaded micelles are placed in the glucose solution for more than 10 hours, and the encapsulation efficiency is still not less than 90%.
- a drug and ginsenoside nanomicelles having a mass of the following combination of minoxidil micelle-encapsulating solution were prepared: 10 mg and 30 mg, 10 mg and 120 mg or 10 mg and 60 mg.
- Soy isoflavones (Isoflavone 40%) l.Og and 9.0 g of the HSE-type ginsenoside nanomicelles of Example 1 were added to a 50 ml beaker, then 10 ml of absolute ethanol was added and dissolved in a vortex mixer, and then filtered through a 0.45 ⁇ m filter paper. It is concentrated under reduced pressure and dried to prepare encapsulated soy isoflavone nanomicelles. After testing, the ginsenoside nanomicelle has a drug loading of at least 99.5%, and the obtained drug-loaded micelles are placed in the glucose solution for more than 10 hours, and the encapsulation efficiency is still not less than 90%.
- encapsulated soy isoflavone nanomicelles of the following combination of the drug and ginsenoside nanomicelles were prepared: 10 mg and 10 mg, 10 mg and 120 mg or 10 mg and 90 mg.
- Resveratrol l.Og and 9.0 g of the Rg2/Rk4/Rg6 type ginsenoside nano-nose micelle of Example 6 were added to a 50 ml vial, then 10 ml of absolute ethanol was added, and then dissolved in a vortex mixer, and then 0.45 ⁇ filter paper was used. After filtration, the filtrate was obtained, concentrated under reduced pressure, and dried to obtain an encapsulated resveratrol nanomicelle.
- Fig. 6A The image of the filtrate is shown in Fig. 6A.
- 1.0 g of resveratrol is added to a 50 ml vial, and then 10 ml of absolute ethanol is added. After dissolution, the obtained image is shown in Fig. 6B; It is obvious that the resveratrol-loaded micelle solution is clear and transparent, while the comparative sample is turbid.
- the ginsenoside nanomicelle has a drug loading of at least 99.5%, and the obtained drug-loaded micelles are placed in the glucose solution for more than 10 hours, and the encapsulation efficiency is still not less than 90%.
- resveratrol nanomicelles having the following combinations of resveratrol and ginsenoside nanomicelles were prepared: lOmg and 10 mg, 10 mg and 120 mg or 10 mg and 90 mg.
- encapsulated vitamin C nanomicelles of the following combinations of the drug and ginsenoside nanomicelles were prepared: lOmg and 10 mg, 10 mg and 120 mg or 10 mg and 90 mg.
- Drug-loaded micelles of vitamin C and Rg6 reverse micelles 30 mg of vitamin C and 180 mg of the Rg6 type ginsenoside nano reverse micelle of Example 13 were added to a 50 ml beaker, and then 2 ml of absolute ethanol was added thereto, which was dissolved in a vortex mixer, filtered through a 0.45 ⁇ m filter paper, concentrated under reduced pressure, and dried.
- the encapsulated vitamin C nanomicelles were prepared. After testing, the ginsenoside nanomicelle has a drug loading of at least 99.5%, and the obtained drug-loaded micelles are placed in the olive oil solution for more than 10 hours, and the encapsulation efficiency is still not less than 90%.
- encapsulated vitamin C nanomicelles of the following combinations of the drug and ginsenoside nanomicelles were prepared: 10 mg and 10 mg, 10 mg and 120 mg or 10 mg and 90 mg.
- encapsulated vitamin C nanomicelles of the following combinations of the drug and ginsenoside nanomicelles were prepared: 10 mg and 10 mg, 10 mg and 120 mg or 10 mg and 90 mg.
- ginsenoside nano reverse micelle 30 mg of vitamin C and 180 mg of the Rg2/Rk4/Rg6 type ginsenoside nano reverse micelle of Example 5 were added to a 50 ml beaker, and then 2 ml of absolute ethanol was added and dissolved in a vortex mixer, filtered through a 0.45 ⁇ m filter paper, and decompressed. After concentration and drying, an encapsulated vitamin C nanomicelle was prepared. After testing, the ginsenoside nanomicelle has a drug loading of at least 99.5%, and the obtained drug-loaded micelles are placed in an olive oil solution for more than 10 hours, and the encapsulation efficiency is still not less than 90%.
- encapsulated vitamin C nanomicelles of the following combinations of the drug and ginsenoside nanomicelles were prepared: 10 mg and 10 mg, 10 mg and 120 mg or 10 mg and 90 mg.
- model and analysis conditions of the particle size analyzer are as follows: Model ELS800; Detection conditions: diameter 1855.3 MH; polydispersity 20994e-001; diffusion parameter 2.5347e-008; temperature 23.2 °C; solvent is water; refractive index 0.9242; viscosity 0.9242; light scattering intensity 6560 CPS.
- the ginsenoside nanomicelle of Example 1 was 480 mg, added to a 5 ml vial and added with 2.0 ml of anhydrous ethanol, and dissolved by stirring with a vortex mixer. After dissolution, it was filtered through a 0.45 ⁇ filter paper, and then 1 ml was dissolved in 99 ml of a 5% dextrose solution.
- the results obtained by a particle size analyzer are shown in Fig. 7, and the data results are shown in Table 19.
- the ginsenoside nanomicelle of Example 2 480 mg was added to a 5 ml vial and 2.0 ml of anhydrous ethanol was added thereto, and dissolved by stirring with a vortex mixer. After dissolution, the mixture was filtered through a 0.45 ⁇ filter paper, and then 1 ml was dissolved in 99 ml of a 5% glucose solution.
- the results obtained by the particle size analyzer are shown in Fig. 8, and the data results are shown in Table 20.
- Example 7 The drug-loaded micelle of Example 7 was applied, and the results were measured by a particle size analyzer as shown in Fig. 4, and the data results are shown in Table 22.
- Example 8 The drug-loaded micelle of Example 8 was applied, and the results were measured by a particle size analyzer as shown in Fig. 5, and the data results are shown in Table 23.
- FIG. 9 is a transmission electron micrograph of the HSE-type ginsenoside nanomicelle of Example 1
- FIG. 10 is a transmission electron micrograph of the Rg3/Rg5/Rkl type ginsenoside nanomicelle of Example 2
- FIG. 11 is Example 5.
- Fig. 12 is a transmission electron micrograph of the paclitaxel-loaded ginsenoside nanomicelle of the application example 1.
- the saponin nanomicelles of the present invention are substantially spherical, have a usual micelle structure, and are structurally stable.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015514348A JP5952494B2 (ja) | 2013-04-28 | 2013-12-04 | サポニンナノミセル、並びにその調製方法、応用及び医薬組成物 |
CN201380026612.1A CN104602679A (zh) | 2013-04-28 | 2013-12-04 | 皂苷纳米胶束及其制备方法、应用和药物组合物 |
US14/370,885 US9421269B2 (en) | 2013-04-28 | 2013-12-04 | Saponin nano micelle, preparing method, application and pharmaceutical composition thereof |
EP13870395.4A EP2815746B1 (en) | 2013-04-28 | 2013-12-04 | Saponin nano-micelle and preparation method, use and pharmaceutical composition thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310155639.2 | 2013-04-28 | ||
CN201310155639.2A CN103271891B (zh) | 2013-04-28 | 2013-04-28 | 人参皂苷纳米胶束及其制备方法、应用和药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014176900A1 true WO2014176900A1 (zh) | 2014-11-06 |
Family
ID=49054118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/088558 WO2014176900A1 (zh) | 2013-04-28 | 2013-12-04 | 皂苷纳米胶束及其制备方法、应用和药物组合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9421269B2 (zh) |
EP (1) | EP2815746B1 (zh) |
JP (1) | JP5952494B2 (zh) |
CN (2) | CN103271891B (zh) |
WO (1) | WO2014176900A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016185509A1 (ja) * | 2015-05-15 | 2016-11-24 | 金氏高麗人参株式会社 | ジンセノサイド組成物 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103271891B (zh) * | 2013-04-28 | 2016-01-06 | 福建南方制药股份有限公司 | 人参皂苷纳米胶束及其制备方法、应用和药物组合物 |
MX2018000286A (es) * | 2015-07-16 | 2018-02-19 | Marinomed Biotech Ag | Metodo para mejorar la solubilidad acuosa de farmacos insolubles o ligeramente solubles en agua. |
US11510859B2 (en) | 2015-07-16 | 2022-11-29 | Marinomed Biotech Ag | Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs |
AU2016309847B2 (en) * | 2015-08-19 | 2019-10-31 | Xiamen Ginposome Pharmaceutical Co., Ltd. | Liposomes with ginsenoside as membrane material and preparations and use thereof |
KR102598793B1 (ko) * | 2015-09-23 | 2023-11-07 | (주)아모레퍼시픽 | 인삼 유래의 엑소좀 유사 베지클을 포함하는 미백용 조성물 |
CN106852928A (zh) * | 2015-12-09 | 2017-06-16 | 北京康爱营养科技股份有限公司 | 一种药物组合物及其用途 |
KR101732876B1 (ko) * | 2016-01-08 | 2017-05-08 | 부산대학교 산학협력단 | 희귀 진세노사이드 CSH1(Rg6)을 유효성분으로 함유하는 항암제 내성 억제용 약학조성물 |
WO2017119767A1 (ko) * | 2016-01-08 | 2017-07-13 | 부산대학교 산학협력단 | 희귀 진세노사이드 CSH1(Rg6)을 유효성분으로 함유하는 항암제 내성 억제용 조성물 |
BE1023538B1 (fr) * | 2016-04-22 | 2017-04-26 | Sil'innov Scrl | Silices mésoporeuses et leur procédé de synthèse |
CN106109482A (zh) * | 2016-07-29 | 2016-11-16 | 陕西巨子生物技术有限公司 | 一种具有抗肿瘤活性的二醇组稀有人参皂苷组合物 |
CN106420776A (zh) * | 2016-07-29 | 2017-02-22 | 陕西巨子生物技术有限公司 | 一种包含稀有人参皂苷Rk1的稀有人参皂苷组合物 |
CN106109483B (zh) * | 2016-07-29 | 2020-02-07 | 陕西巨子生物技术有限公司 | 具有抗肿瘤活性的二醇组/三醇组稀有人参皂苷组合物 |
US20180050005A1 (en) * | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Concentrated Solution of 17-Hydroxydocosahexaenoic Acid |
CN106550945B (zh) * | 2016-10-26 | 2019-03-22 | 中国中医科学院中药研究所 | 人参皂苷混合物及其在作为双向端粒调节剂中的应用 |
KR101996713B1 (ko) * | 2017-01-18 | 2019-07-04 | 가천대학교 산학협력단 | 진세노사이드 및 인지질 기반 지질나노입자 및 이의 제조방법 |
CN108339000B (zh) * | 2017-01-22 | 2021-08-03 | 上海弘医堂生物医药科技有限公司 | 一种人参属植物提取物及其药物组合物和应用 |
CN107320448A (zh) * | 2017-08-29 | 2017-11-07 | 天津中医药大学 | 一种包裹人参皂苷Rg3的球形胶束及其制备方法与应用 |
JP7018642B2 (ja) * | 2017-09-25 | 2022-02-14 | 株式会社バスクリン | 植物由来成分のマイクロエマルション製剤 |
CN108420793B (zh) * | 2017-12-26 | 2021-09-24 | 厦门本素药业有限公司 | 一种空白混合胶束及其制备方法和应用 |
CN108273042A (zh) * | 2018-04-25 | 2018-07-13 | 福州大学 | 一种人参皂苷-胰岛素纳米凝胶及其制备方法与应用 |
CN109045053B (zh) * | 2018-07-02 | 2021-06-04 | 西安巨子生物基因技术股份有限公司 | 治疗白细胞减少症的人参皂苷组合物与应用 |
CN109223582A (zh) * | 2018-10-31 | 2019-01-18 | 延边大学 | 具有抗皮肤衰老功能的二醇型人参皂苷纳米乳及其制备方法 |
CN110613724B (zh) * | 2018-11-07 | 2021-03-12 | 山东大学齐鲁医院 | 一种具有治疗肝细胞癌功效的药物 |
CN109875956A (zh) * | 2019-04-03 | 2019-06-14 | 福州大学 | 一种人参皂苷-华法林自组装纳米凝胶及其应用 |
WO2020209567A1 (ko) * | 2019-04-09 | 2020-10-15 | 충남대학교산학협력단 | 진세노사이드 rg2, rg4, rg6 및 rh1을 포함하는 혼합물(rgx-365)을 유효성분으로 포함하는 미세먼지에 의한 호흡기 질환 예방 또는 치료용 조성물 및 이의 제조방법 |
CN111358803B (zh) * | 2020-04-24 | 2021-05-07 | 陕西巨子生物技术有限公司 | 包含稀有人参皂苷Rg6和F4的改善睡眠药物组合物 |
CN113827487B (zh) * | 2021-09-23 | 2022-10-14 | 茵素科技(广州)有限公司 | 一种壳材、纳米载体及其用途 |
CN113786369A (zh) * | 2021-11-05 | 2021-12-14 | 青岛科技大学 | 一种含人参总皂苷的天然抗氧化纳米组合物及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101824065A (zh) | 2009-12-03 | 2010-09-08 | 吉林农业大学 | 人参皂苷次级苷Rh1的脂肪酸单酯类化合物及制备方法 |
CN102174191A (zh) | 2011-03-07 | 2011-09-07 | 天津科技大学 | 聚乙二醇和脂溶性化合物的连接物在生物催化中的应用 |
CN102603847A (zh) | 2010-11-18 | 2012-07-25 | 吉林农业大学 | 人参皂苷Rh2脂肪酸酯类化合物制备方法及其医药用途 |
CN102766187A (zh) | 2012-06-21 | 2012-11-07 | 李晓辉 | 人参皂苷Compound-K酯类衍生物及其在制备防治动脉粥状硬化的药物中的应用 |
CN103271891A (zh) * | 2013-04-28 | 2013-09-04 | 福建南方制药股份有限公司 | 人参皂苷纳米胶束及其制备方法、应用和药物组合物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ500779A (en) * | 1997-05-20 | 2001-06-29 | Galenica Pharmaceuticals Inc | Triterpene saponin analogs having adjuvant and immunostimulatory activity |
JP4777776B2 (ja) * | 2003-08-18 | 2011-09-21 | ユーユー インコーポレイテッド | 酢を利用した人参製剤及びこれの製造方法 |
KR100557779B1 (ko) * | 2004-06-11 | 2006-03-07 | 주식회사 유니젠 | 집중력 및 기억력 저하의 예방 또는 개선을 위한 인삼조성물 |
KR100740609B1 (ko) * | 2004-06-11 | 2007-07-18 | 주식회사 유니젠 | 진세노사이드를 포함하는 혈관 협착 및 재협착 예방 또는치료용 조성물 |
CA2614700C (en) * | 2005-07-14 | 2011-07-19 | National Institute Of Pharmaceutical R&D Co., Ltd. | Medicinal composition containing ginseng secondary glycosides, its preparation method and application |
CN1869055A (zh) * | 2006-06-21 | 2006-11-29 | 海南亚洲制药有限公司 | 一种从人参叶中提取分离人参皂苷单体的方法 |
CN1869059B (zh) | 2006-06-21 | 2012-04-18 | 海南亚洲制药有限公司 | 从人参叶中制备人参皂苷单体的方法 |
CN102453072A (zh) | 2010-10-26 | 2012-05-16 | 中国医学科学院药物研究所 | 人参皂苷Rg1的制备方法 |
-
2013
- 2013-04-28 CN CN201310155639.2A patent/CN103271891B/zh active Active
- 2013-12-04 WO PCT/CN2013/088558 patent/WO2014176900A1/zh active Application Filing
- 2013-12-04 EP EP13870395.4A patent/EP2815746B1/en active Active
- 2013-12-04 JP JP2015514348A patent/JP5952494B2/ja active Active
- 2013-12-04 CN CN201380026612.1A patent/CN104602679A/zh active Pending
- 2013-12-04 US US14/370,885 patent/US9421269B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101824065A (zh) | 2009-12-03 | 2010-09-08 | 吉林农业大学 | 人参皂苷次级苷Rh1的脂肪酸单酯类化合物及制备方法 |
CN102603847A (zh) | 2010-11-18 | 2012-07-25 | 吉林农业大学 | 人参皂苷Rh2脂肪酸酯类化合物制备方法及其医药用途 |
CN102174191A (zh) | 2011-03-07 | 2011-09-07 | 天津科技大学 | 聚乙二醇和脂溶性化合物的连接物在生物催化中的应用 |
CN102766187A (zh) | 2012-06-21 | 2012-11-07 | 李晓辉 | 人参皂苷Compound-K酯类衍生物及其在制备防治动脉粥状硬化的药物中的应用 |
CN103271891A (zh) * | 2013-04-28 | 2013-09-04 | 福建南方制药股份有限公司 | 人参皂苷纳米胶束及其制备方法、应用和药物组合物 |
Non-Patent Citations (5)
Title |
---|
CAO MAN; ZHANG JIE; SONG XINBO; MA BAIPING: "Advances in ginsenoside Rh2 and its derivatives", WORLD SCIENCE AND TECHNOLOGY-MODERNIZATION OF TRADITIONAL CHINESE MEDICINE AND MATERIA MEDICA, vol. 14, no. 6, 2012 |
DAI, XINGXING ET AL.: "Mesoscopic Simulation Study on Influencing Factors on Micellization of Ginsenoside Ro, MODERNIZATION OF TRADITIONAL CHINESE MEDICINE AND MATERIA MEDICA", SEMINAR: CHINESE MEDICINE INFORMATION ENGINEERING, vol. 14, no. 4, April 2012 (2012-04-01), pages 1767 AND 1772, XP008174581 * |
LI, WENYUAN ET AL.: "The Advance of Nano-micelles Used as Drug Delivery", CHINA LICENSED PHARMACIST, vol. 16, no. 12, December 2009 (2009-12-01), pages 36 - 39, XP008174632 * |
LIU MEI; WANG LI; HU KAILI; FENG JIANFANG: "Modification and stability of ginsenoside Rgl PEG", CHINA JOURNAL OF CHINESE MATERIA MEDICA, vol. 37, no. 10, May 2012 (2012-05-01), pages 1378 - 1382 |
See also references of EP2815746A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016185509A1 (ja) * | 2015-05-15 | 2016-11-24 | 金氏高麗人参株式会社 | ジンセノサイド組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP5952494B2 (ja) | 2016-07-13 |
CN104602679A (zh) | 2015-05-06 |
CN103271891B (zh) | 2016-01-06 |
CN103271891A (zh) | 2013-09-04 |
EP2815746A1 (en) | 2014-12-24 |
EP2815746A4 (en) | 2015-09-09 |
JP2015516990A (ja) | 2015-06-18 |
EP2815746B1 (en) | 2020-09-09 |
US9421269B2 (en) | 2016-08-23 |
US20150297727A1 (en) | 2015-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014176900A1 (zh) | 皂苷纳米胶束及其制备方法、应用和药物组合物 | |
Tang et al. | Nucleosome-inspired nanocarrier obtains encapsulation efficiency enhancement and side effects reduction in chemotherapy by using fullerenol assembled with doxorubicin | |
Wang et al. | In vitro and in vivo anticancer activity of a novel puerarin nanosuspension against colon cancer, with high efficacy and low toxicity | |
Gao et al. | Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions | |
Xiong et al. | Design and evaluation of a novel potential carrier for a hydrophilic antitumor drug: Auricularia auricular polysaccharide-chitosan nanoparticles as a delivery system for doxorubicin hydrochloride | |
Fernandes et al. | Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy | |
CN109833298A (zh) | 以人参皂苷衍生物为膜材的新型空白脂质体、其制备方法及应用 | |
Hesami et al. | Synthesis and characterization of chitosan nanoparticles loaded with greater celandine (Chelidonium majus L.) essential oil as an anticancer agent on MCF-7 cell line | |
WO2017021983A1 (en) | Particulate delivery systems | |
Deng et al. | Tea saponins as natural emulsifiers and cryoprotectants to prepare silymarin nanoemulsion | |
Suo et al. | Lentinan as a natural stabilizer with bioactivities for preparation of drug–drug nanosuspensions | |
Tian et al. | Fabrication of nanosuspensions to improve the oral bioavailability of total flavones from Hippophae rhamnoides L. and their comparison with an inclusion complex | |
Shang et al. | Metal ions-mediated self-assembly of nanomedicine for combinational therapy against triple-negative breast cancer | |
Mi et al. | Structural characterization and anti-inflammatory properties of green synthesized chitosan/compound K‑gold nanoparticles | |
Shi et al. | Construction of inulin-based selenium nanoparticles to improve the antitumor activity of an inulin-type fructan from chicory | |
EP3638214B1 (en) | Nanoparticles as delivery vehicles of active ingredients and methods for the production thereof | |
EP3616726B1 (en) | Protein particle wrapped with medicine insoluble in water and preparation method therefor | |
Rajput et al. | Design of lactoferrin functionalized carboxymethyl dextran coated egg albumin nanoconjugate for targeted delivery of capsaicin: Spectroscopic and cytotoxicity studies | |
CN111202719A (zh) | 一种活性天然产物纳米载药系统及其制备方法与应用 | |
CN101254184B (zh) | 丹参酚酸b磷脂复合物及其制备方法 | |
Noreen et al. | Polymeric complex nanocarriers of Mangifera indica gum & chitosan for methotrexate delivery: Formulation, characterization, and in vitro toxicological assessment | |
CN113244234B (zh) | 一种金色酰胺醇酯-半枝莲碱-棕榈酸酯自组装纳米粒及其制备方法和应用 | |
Polat et al. | Recent advances in chitosan-based systems for delivery of anticancer drugs | |
CN110960491A (zh) | 一种负载丹参酮ⅡA的水溶性壳聚糖/γ-聚谷氨酸纳米复合物的制备方法及应用 | |
KR20200064786A (ko) | 알로에 활성성분을 함유하는 나노입자 및 이를 함유하는 화장료조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 14370885 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013870395 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015514348 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13870395 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |